RedHill Biopharma Ltd. (NASDAQ: RDHL) is an Israeli biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer. The company is working to develop proprietary, orally administered, small molecule drugs. RedHill’s current pipeline of proprietary products includes RHB-105, an oral combination therapy for Helicobacter pylori infection, which has completed the first phase III study.  For more information, visit the company’s website at www.redhillbio.com.